Table 2. Fibroblast Growth Factor 23 (FGF23) and Prevalent Atrial Fibrillationa.
| Variable | Cases/Total No. | Per 1-U Increase in Natural Log FGF23 | FGF23 Quartile, RU/mL | ||||
|---|---|---|---|---|---|---|---|
| Quartile 1 (≤95.9) | Quartile 2 (96.0-145.6) | Quartile 3 (145.7-239.2) | Quartile 4 (>239.2) | P for Trend | |||
| Prevalence, No./total No. (%) | 660 | 660/3876 (17.0) | 117/969 (12.1) | 124/969 (12.8) | 185/969 (19.1) | 234/969 (24.1) | NA |
| Odds ratio (95% CI) | |||||||
| Unadjusted | 660/3876 | 1.51 (1.36-1.68) | 1 [Reference] | 1.07 (0.82-1.40) | 1.72 (1.34-2.21) | 2.32 (1.82-2.96) | <.001 |
| Plus demographic factorsb | 660/3876 | 1.53 (1.37-1.71) | 1 [Reference] | 1.03 (0.78-1.35) | 1.66 (1.28-2.14) | 2.30 (1.80-2.95) | <.001 |
| Plus cardiovascular risk factorsc | 655/3847 | 1.36 (1.21-1.54) | 1 [Reference] | 0.95 (0.71-1.25) | 1.44 (1.10-1.88) | 1.83 (1.40-2.40) | <.001 |
| Plus CKD-specific factorsd | 655/3847 | 1.44 (1.27-1.64) | 1 [Reference] | 1.00 (0.75-1.33) | 1.62 (1.22-2.15) | 2.18 (1.62-2.93) | <.001 |
| Plus markers of mineral metabolisme | 633/3729 | 1.46 (1.27-1.67) | 1 [Reference] | 1.04 (0.78-1.39) | 1.63 (1.22-2.19) | 2.30 (1.69-3.13) | <.001 |
Abbreviations: CKD, chronic kidney disease; NA, not applicable; RU, reference units.
a
Continuous results are reported as odds ratios per 1-U increase in natural log-transformed FGF23.
b
Adjusts for age, sex, and race/ethnicity.
c
Adjusts for factors in model 1 and for cardiovascular disease, systolic blood pressure, diabetes, smoking, and diuretic use.
d
Adjusts for factors in model 2 and for estimated glomerular filtration rate and ratio of urinary albumin to creatinine.
e
Full multivariable model adjusts for factors in model 3 and for levels of calcium, phosphate, and parathyroid hormone.